Company news
Axsome Therapeutics, Inc. news in 2023
Axsome Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting
December 10, 2023
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
December 6, 2023
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
November 21, 2023
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
November 20, 2023
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 5, 2023
Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023
November 1, 2023
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference
October 23, 2023
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
October 10, 2023
Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6
October 9, 2023
Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week
October 1, 2023
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
September 20, 2023
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
September 6, 2023
Axsome Therapeutics to Present at Three Upcoming Investor Conferences
September 4, 2023
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 6, 2023
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
July 11, 2023
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
July 6, 2023
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
June 29, 2023
Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock
June 27, 2023
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
June 26, 2023
Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023
May 31, 2023
Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 29, 2023
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
May 7, 2023
Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference
May 2, 2023
Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month
April 30, 2023
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academ...
April 20, 2023
Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 13, 2023
Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8
April 12, 2023
Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
February 28, 2023
Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 26, 2023
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
February 21, 2023
Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 6, 2023
Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27
January 30, 2023
Calls in 2023
- Axsome Therapeutics (NASDAQ:AXSM) Q3 2023 Earnings Call
Nov 6, 2023
Transcript - Axsome Therapeutics (NASDAQ:AXSM) Q2 2023 Earnings Call
Aug 7, 2023
Transcript - Axsome Therapeutics (NASDAQ:AXSM) Q1 2023 Earnings Call
May 8, 2023
Transcript - Axsome Therapeutics (NASDAQ:AXSM) Q4 2022 Earnings Call
Feb 27, 2023
Transcript
Decks in 2023
- Investor Day (December 2023)
Investor day · 95 slides · Dec 7, 2023
- Investor Presentation (August 2023)
Investor deck · 35 slides · Aug 15, 2023
- Investor Presentation (June 2023)
Investor deck · 34 slides · Jun 13, 2023